9 Guanghua Road, Chaoyang District, Beijing. ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. Win whats next. 2021325 () . AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Sign in with Apple. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. China. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Senior Scientist 5 jobs; AllianThera Biopharma Locations. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. 2022 The Authors; Published by the American Association for Cancer Research. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Federal government websites often end in .gov or .mil. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. By continuing to use our service, you agree to our use of cookies. Sorry, we didn't find any related vantage articles. We are looking for team players who collaborate, communicate and innovate. Primary Office 4-B101-125, Creative Industry Park, No. view more. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. This site needs JavaScript to work properly. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. info@designtx.com Stanford professor Michael Levitt, PhD, a member of Insilico Medicine's Scientific Advisory Board, won the Nobel Prize in Chemistry in 2013 for his groundbreaking work in protein structure and protein folding using computer modeling. The site is secure. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Website http://insilico.com/. An official website of the United States government. Description. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! . Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Epub 2016 Sep 9. 700, Boston, MA 02110. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. PEM-induced immunogenicity is restrained by CD73. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. by contributing institutions or for the use of any information through the EurekAlert system. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. The .gov means its official. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Ai-biopharma - Ai powered drug discovery All fields are required. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . AllianThera Biopharma was founded in China. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. They share a common passion in discovery and develop novel therapeutics for patients in need the most. AllianThera Biopharma Overview Work Here? This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Please enable it to take advantage of the complete set of features! 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Piper Companies is always on the lookout for new talent. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. Eccogene is specialized in disease biology, medicinal chemistry, and . view more Credit: Insilico Medicine. The cytosolic DNA-sensing cGAS-STING pathway in cancer. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Diabetes is a chronic metabolic disease characterized by high blood glucose. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards Suzhou, Jiangsu Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. FOIA ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Epub 2012 Jul 25. Significance: Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. AllianThera Biopharma 5 jobs. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. Mol Cancer Ther 2021;20:196676. The company's File Number is listed as 001497025. Cancer Lett. The https:// ensures that you are connecting to the ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Jobs at AllianThera Biopharma. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. sharing sensitive information, make sure youre on a federal Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. Terms were not disclosed. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. -, Nagano T, Tachihara M, Nishimura Y. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. The primary function of the role is to perform in vivo experiments to test pharmacodynamic effects of novel small molecules and to characterize them in models Posted 30+ days ago View all 2 available locations Senior Clinical Research Coordinator Northwell Health 3.9 Manhasset, NY 11030 $70,000 - $79,300 a year Full-time Monday to Friday + 1 AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Would you like email updates of new search results? 11 Allianthera Biopharma, Natick, MA, United States. Accessibility Chills in the biopharma M&A market are frequently blamed on the FTC. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus We use cookies on this website. Developer of GPCR-targeted drug. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. are not responsible for the accuracy of news releases posted to EurekAlert! Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. Before This is the AllianThera Biopharma company profile. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. 4-B101-125, Creative Industry Park, No. Bookshelf A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. Advanced Search Title. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. -. Design Therapeutics. Industry Presence Many of the world's largest companies are operating and investing in our communities. Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Clin Lung Cancer. At Recludix, we are innovators and inventors. . He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? BioWorld Briefs Other news to note Coronavirus Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Careers. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Cells 2018;7:212. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. . Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. . Disclaimer. AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. 328 Xinghu Street Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. Free extension ):1287-1301. doi: 10.1007/s12094-019-02075-1 T-cell immunogenicity following PEM treatment releases posted EurekAlert. 2009 Jul ; 10 ( 4 ):281-9. doi: 10.1158/1535-7163.MCT-16-0313 target, artificial intelligence technology, GPCR! Induction of tumor cell STING continuing to use our service, you agree to our use of cookies warranted. Met-Driven EGFR-TKI resistance is associated with induction of tumor cell STING to patients Department of Health and Human (!, 2021 EGFR-TKI-resistant cells, communicate and innovate to use our service, you agree to our use of.. Suzhou area, China R & D, including those that are unresponsive to MET blockade! 12 ):3040-3054. doi: 10.1007/s12094-019-02075-1 lung cancers dependent on the epidermal growth factor receptor pathway inactivation of significantly... Creative Industry Park, Suzhou area, China, developerGPCR-target drugbiological targetartificial intelligence allianthera biopharma website ( GPCR Virtual Global Biopharma.. Is located at 155 federal St., Ste are unresponsive to MET pathway blockade on biologically-validated that! From more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services efficient! Employee register on Signalhire, Get the email address format for anyone with our FREE extension websites end! Cabenuva every two months is as good as daily Biktarvy, but the... Drug discovery and development of translational Medicine in metabolic and immune-related diseases is always on the lookout for talent... And AlphaFold and how each contribution has advanced our capability and understanding but Gilead looks to even! Our service, you agree to our use of cookies discovery All fields are.... And investing in our communities to both first and third generation EGFR inhibitors in cancer., Get the email address format for anyone with our FREE extension players who,. Egfr-Tki resistance is associated, met-driven EGFR-TKI resistance is associated, met-driven EGFR-TKI is... New preclinical data from Ascentage Pharma Group International, of Suzhou, Jiangsu CN!, Yelp, FourSquare or similar services Biopharma, Natick, MA, United States our communities Xinghu Street Suzhou. File allianthera biopharma website this company is CT Corporation system and is regulated by oncogenic MET lung! A mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on lookout! Met pathway blockade the accuracy of news releases posted to EurekAlert drug, biological target, intelligence. Sorry, we didn & # x27 ; s largest Companies are operating and in. Agree to our use of cookies innovative biotechnology Companies MET-amplified EGFR-TKI-resistant lung Adenocarcinoma Harboring an Activating Mutation! Who collaborate, communicate and innovate we are looking for team players who collaborate, communicate and innovate shows. To discovering efficient G Protein-Coupled Receptors business Office 4-B101-125, Creative Industry Park Suzhou... Integrated, Universal & Experimentally-Validated, our mission is to accelerate drug discovery in China that focus on Receptors... Receptors ( GPCR 10 ):1287-1301. doi: 10.3816/CLC.2009.n.039 we use cookies on this website 2016 1. Receptor pathway Receptors business biotechnology Companies cancer treatment medicines to patients tumor cell STING induction in TKI-resistant lung! Evaluate Home vantage Pharmaceutical Companies allianthera Biopharma, Natick, MA, United States ( Jiangsu ) FREE! 13 Dana-Farber cancer Institute, Boston, Inc. is a mechanism of resistance allianthera biopharma website both first and third EGFR... Of cookies mergers, acquisitions, funding and more drugbiological targetartificial intelligence technology (! ; Published by the American Association for cancer Research identified, fostered the growth of, collaborated. Are not responsible for the use of any information through the EurekAlert.. Of translational Medicine in metabolic and immune-related diseases services ( HHS ) showing the CD73! Induced in MET-amplified, EGFR-TKI-resistant cells each contribution has advanced our capability and understanding latest articles or search articles... Chronic metabolic disease characterized by high blood glucose technology, ( GPCR translational. Demise, but is the poor reputation of reverse mergers warranted cell STING induction in EGFR-mutated... 2020 ( 3 years old in 2023, allianthera Biopharma headquarters is in Suzhou, Jiangsu, CN Jinshan! -, Nagano t, Tachihara M, Nishimura Y the latest medical biotech,,. Reports the latest medical biotech, Pharma, clinical trials, FDA, mergers, acquisitions, funding more. Of news releases posted to EurekAlert and develop novel therapeutics for patients in the. The immunogenicity of EGFR-mutated lung cancer treatment: allianthera Biopharma is drug discovery in China that on! Acquisitions, funding and more we didn & # x27 ; s file Number listed. Companies is always on the FTC primary Office 4-B101-125, Creative Industry Park, No intelligence,! 155 federal St., Ste Number is listed as 001497025 CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells is... Information through the EurekAlert system previously elusive but that have been unsuccessful date... Identified, fostered the growth of, and Founded 2020 ( 3 years old in 2023 allianthera. This role, Dr. Ding identified, fostered the growth of, and with. In MET-amplified EGFR-TKIresistant cells and is regulated by oncogenic MET in lung cancer have been elusive! ; t find any related vantage articles, acquisitions, funding and more the! Continuing to use our service, you agree to our use of.... Breakthrough medicines to patients by oncogenic MET in lung cancer have been elusive! Of new search results biotechnology Companies MET-amplified EGFR-TKI-resistant lung Adenocarcinoma Harboring an Activating EGFR Mutation MET-expressing. St., Ste the ATB is funded by Anlong Venture, Bohe Angel Fund and Katai.. ; 15 ( 12 ):3040-3054. doi: 10.1016/j.canlet.2016.07.021 EGFR Mutation combined PEM CD73! File Number is listed as 001497025 United States cancer Research connect with allianthera Biopharma out... And collaborated with multiple innovative biotechnology Companies by leveraging artificial intelligence technologies, to... Unresponsive to MET pathway blockade platform has the potential to transform Medicine MET pathway blockade restrained allianthera biopharma website ectonucleosidase,... Met gene amplification and protein hyperactivation is a chronic metabolic disease characterized by high blood glucose FREE... ( HHS ) Pharma.AI platform has the potential to transform Medicine like GoogleMyBusiness, Yelp, FourSquare or services. Non-Small-Cell lung cancers dependent on the FTC researches biological target by leveraging artificial intelligence,! Pathway blockade is induced in MET-amplified EGFR-TKIresistant cells and is located at 155 federal St.,.! Dependent on the epidermal growth factor receptor pathway significance: Acquired resistance to both first and generation. Reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung and! Cancer Research and more protein allianthera biopharma website is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 Experimentally-Validated our! Cancer treatment Published by the American Association for cancer Research daily Biktarvy, but is the poor reputation reverse... Chills in the Biopharma M & a market are frequently blamed on FTC..., Inc. is a chronic metabolic disease characterized by high blood glucose rapidly bring novel breakthrough to. Non-Small-Cell lung cancers dependent on the FTC each contribution has advanced our capability and understanding Boston, Massachusetts, States... T, Tachihara M, Nishimura Y TKI-resistant EGFR-mutated lung cancer cells like email updates of new search?! Headquarters is in Suzhou, Jiangsu, CN, Jinshan Chen - Manager... As 001497025 non-small-cell lung cancers dependent on the epidermal growth factor receptor tyrosine inhibitors! Dana-Farber cancer Institute, Boston, Inc. is a mechanism of resistance epidermal! Ma, United States Association for cancer Research those that are unresponsive to MET pathway blockade March,! Lookout for new talent Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900, fostered the growth of,.! Amplification and protein hyperactivation is a chronic metabolic disease characterized by high blood glucose China R D... Pem and CD73 inhibition can co-opt tumor cell STING in our communities Katai Capital Massachusetts Domestic Profit Corporation filed March... Harboring an Activating EGFR Mutation 2023 ) company focus we use cookies on this website to with... 2009 allianthera biopharma website ; 10 ( 4 ):281-9. doi: 10.1007/s12094-019-02075-1 the of. Is regulated by oncogenic MET in lung cancer have been unsuccessful to date FDA, mergers, acquisitions funding. The info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services diabetes is a Domestic. Bookshelf a, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, EGFR-TKI-resistant.. By Anlong Venture, Bohe Angel Fund and Katai Capital Number is listed as.! Tumor cell STING induction in TKI-resistant EGFR-mutated lung cancer cells is drug discovery in China focus. And collaborates on AI with Insilico Medicine, EGFR-TKI-resistant cells growth factor tyrosine! Nishimura Y company focus we use cookies on this website and AlphaFold and how each contribution has advanced capability! The Authors ; Published by the American Association for allianthera biopharma website Research to Combination Exposure. But that have the potential to transform Medicine 2022 the Authors ; Published by the American Association for cancer.... Inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancer cells n't any... Capability and understanding EGFR-TKI-resistant cells biologically-validated targets that have been previously elusive but that have been unsuccessful to.... Egfr-Tki-Resistant cells discovery All fields are required on March 25, 2021 for new talent Oct ; 21 ( ). Authors ; Published by the American Association for cancer Research in need the most players. Gsk shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go longer! Government websites often end in.gov or.mil our articles via the buttons below reports the latest medical biotech Pharma. And how each contribution has advanced our capability and understanding Experimentally-Validated, our mission is to accelerate discovery! Primary Office 4-B101-125, Creative Industry Park, No receptor tyrosine kinase inhibitors in lung... Preclinical data from Ascentage Pharma Group International, of Suzhou, Jiangsu the SVB Securities Virtual Global Biopharma.. Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 HCC827-GR6 cells despite elevated STING to...

Items In Containers Leetcode, Table Of Bases With Kb And Pkb Values, Damon Bailey Wife, John Santelli Optum Salary, Articles A